Company Analysis
Sign in

Immuneering Corporation (IMRX)

Nasdaq: IMRX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.9
◀ Past 4.1● Present 5.7▶ Future 4.6
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
Revenue$0.00-100.0%
Net income-$53.5M-5.9%
Earnings per share$-1.88+1.6%
Operating cash flow-$49.0M-11.0%
Cash$59.4M-18.2%
Debtn/a
Shareholders’ equity$90.6M-17.5%
Shares, diluted28.4M+7.7%
Return on equity-25.6%
The recordfrom its filings
Filings in 202644
Newest filingNov 9 · 4
Annual reportMar 6, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$300,000
Patents granted3
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$66.5MCash from operations -$61.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 9, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 29, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 29, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Jul 28, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Jul 17, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton IMRX · research, not advice